Literature DB >> 12170570

Update on anorexia and cachexia.

Florian Strasser1, Eduardo D Bruera.   

Abstract

Declining physical, emotional, and social function as a result of anorexia and cachexia are considerable contributors to discomfort for cancer patients and their families, and they impair the patient's ability to express optimal physical and psychosocial potential as long as possible. This decline no longer has to be accepted as an indispensable sequel to advanced cancer, just as pain is no longer considered to be unavoidable. A routine screening for anorexia and cachexia and associated symptoms is necessary, as is a careful, comprehensive assessment, because the condition is not always obvious. Decisions about anorexia and cachexia treatment are guided by prioritizing the different, concurrent physical, psychosocial, and existential problems and by considering the natural course of the cancer and the effects of antineoplastic therapies. Reversible causes for anorexia and cachexia need to be identified and treated, if appropriate. Nutritional interventions are often indicated; patients with a predominant starvation component and without inflammation may profit the most. New pharmacologic therapies for primary anorexia and cachexia syndrome are expected to enter clinical practice soon; however, until then, treatment with corticosteroids, progestins, or prokinetics may be indicated for some patients. To understand a multicausal syndrome, multimodal and interdisciplinary therapy is required. Specialist palliative care services can be helpful to provide, hand-in-hand with the disease specialists [172], assessment and management of psychophysical symptoms and sociospiritual needs of patients during the course of the illness and at the end of life [173]. Research efforts aim to better characterize subgroups of patients suffering from secondary causes of anorexia and cachexia and to elucidate the mechanisms involved in the primary anorexia and cachexia syndrome. Increasingly individualized treatments are expected with combination treatments that involve different mechanisms including nutrition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170570     DOI: 10.1016/s0889-8588(02)00011-4

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  14 in total

1.  Nutritional status of cancer patients and its relationship to function in an inpatient rehabilitation setting.

Authors:  Ying Guo; J Lynn Palmer; Guddi Kaur; Susan Hainley; Beth Young; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2004-12-03       Impact factor: 3.603

2.  Ultrasonographic Follow-up of the Multistep Protocol for Prostate Cancer Induction in Wistar Rats.

Authors:  MÁrio Ginja; Paula A Oliveira; Ana I Faustino-Rocha; Fernanda Seixas; Rita Ferreira; Jessica Silva; Maria J Pires; Margarida Fardilha
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 3.  Anorexia in cancer: role of feeding-regulatory peptides.

Authors:  Simona Perboni; Akio Inui
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 4.  What to eat when off treatment and living with involuntary weight loss and cancer: a systematic search and narrative review.

Authors:  Jane B Hopkinson; Ikumi Okamoto; Julia M Addington-Hall
Journal:  Support Care Cancer       Date:  2010-08-06       Impact factor: 3.603

5.  Disruptions in the organization of meal preparation and consumption among older cancer patients and their family caregivers.

Authors:  Julie L Locher; Caroline O Robinson; F Amos Bailey; William R Carroll; Douglas C Heimburger; M Wasif Saif; Gabriel Tajeu; Christine S Ritchie
Journal:  Psychooncology       Date:  2010-09       Impact factor: 3.894

Review 6.  [Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients].

Authors:  F Nauck; E Klaschik
Journal:  Schmerz       Date:  2004-06       Impact factor: 1.107

7.  Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers.

Authors:  Anne E Utech; Eiriny M Tadros; Teresa G Hayes; Jose M Garcia
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-31       Impact factor: 12.910

8.  Emerging markers of cachexia predict survival in cancer patients.

Authors:  Patrizia Mondello; Antonio Lacquaniti; Stefania Mondello; Davide Bolignano; Vincenzo Pitini; Carmela Aloisi; Michele Buemi
Journal:  BMC Cancer       Date:  2014-11-16       Impact factor: 4.430

9.  Estimation of Cachexia among Cancer Patients Based on Four Definitions.

Authors:  Kathleen M Fox; John M Brooks; Shravanthi R Gandra; Richard Markus; Chiun-Fang Chiou
Journal:  J Oncol       Date:  2009-07-01       Impact factor: 4.375

10.  Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial.

Authors:  Valiollah Mehrzad; Rohollah Afshar; Mojtaba Akbari
Journal:  Adv Biomed Res       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.